Bryan Garnier - Novo Nordisk (novob) NOVO NORDISK: Upgrade to the FY guidance on the back of better-than-expected market conditions | NEUTRAL | DKK462 vs. 450

Report

Bryan Garnier

Eric Le Berrigaud

NOVO NORDISK: Upgrade to the FY guidance on the back of better-than-expected market conditions | NEUTRAL | DKK462 vs. 450

NOVO NORDISK - NEUTRAL | DKK462 vs. 450 (+5%)
Upgrade to the FY guidance on the back of better-than-expected market conditions

An anticipated disclosure of top-line Q3 figures
Raised FY guidance is a very good surprise
Is there any transition phase at Novo-Nordisk any longer?

09/10/2020 3 EN

Underlying

Novo Nordisk

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Eric Le Berrigaud

Other Reports on these Companies

New Street Research

Novo - Negative Mix A Major Concern (SELL, TP DKK350, 15pgs)

We have rebuilt our Wegovy & Ozempic models for volume, price & mix to account for the divergent dynamics by channel. We show that 1) Ozempic volume forecasts remain too high and NRx has now turned negative, 2) Mix is set to worsen dramatically for Ozempic such that 2027 group EPS growth is 0% on our numbers, 3) The Wegovy inflection implied in our forecasts is likely best case scenario w.r.t compounding & CVS, yet we are at the low end of guidance. We are modestly below cons. sales in 2025&26 with our optimistic assumptions but 14% below in 2027 due to our analysis on channel mix, IRA & prici...

EUR 4277.50

May 20, 2025 May 20, 2025 1 EN

New Street Research

MFN Drug Pricing - Impact and Implementation (Thematic, 5pgs)

Ahead of today’s signing of an Executive Order to introduce a Most Favoured Nation approach to drug pricing in the US, we show that net pricing in the EU is c.50% lower than in the US & which companies have most to lose from MFN. We also show that, in reality,

EUR 4277.50

May 12, 2025 May 12, 2025 1 EN

New Street Research

Novo - Worrying Times (SELL, TP DKK350 [460], 13pgs)

Following the orfo’ P3 data, latest Wegovy scrips & rapidly faltering Ozempic growth, we conduct a wholesale review of our obesity market model, Wegovy & Ozempic scrip models & our Novo financial model. The outcome of this analysis is that we downgrade our 2030 sales by 20% and EPS by 24%. We now assume Novo only achieve a 25% obesity market share by 2030. We are 19% below consensus sales & 23% below EPS in 2030. We also provide a detailed hypothesis as to why US obesity demand growth is so lacklustre & conclude demand growth will be slow in the absence of Medicare approval. PT cut to DKK350 &...

EUR 4277.50

April 22, 2025 April 22, 2025 1 EN

H&M: modest signs of improvement

While still showing a contraction YoY, Q2 margins improved sequentially versus Q1, lending more credibility to the company’s guidance for a positive inflexion point expected in H2 2025. However, H&M remains particularly sensitive to fluid external factors such as promotional activity, freight c

20h / 1m 20h / 1m 1 EN

Cédric Rossi

Cédric Rossi

Emerging consolidator in Germany’s optical retail sector

After announcing its ambition to enter the optical sector earlier this month, the German software company The Platform Group (TPG) has already acquired four optical players in Germany. In addition to joining TPG’s MyGlasses.de online platform to implement an omnichannel approach, these acquisitions

June 26, 2025 June 26, 2025 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Fastned: EUR34.7m bond issue

Yesterday, Fastned announced it has raised more than EUR34.7m from its second bond issue to retail investors this year, with EUR28.8m contributed in new investments and EUR5.9m rolled from earlier tranches. This brings the total amount of retail bonds raised in 2025 to more than EUR71m (vs EUR82m i

June 25, 2025 June 25, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

NOVO NORDISK: Upgrade to the FY guidance on the back of better-than-expected market conditions | NEUTRAL | DKK462 vs. 450

Novo - Negative Mix A Major Concern (SELL, TP DKK350, 15pgs)

MFN Drug Pricing - Impact and Implementation (Thematic, 5pgs)

Novo - Worrying Times (SELL, TP DKK350 [460], 13pgs)

H&M: modest signs of improvement

Emerging consolidator in Germany’s optical retail sector

Fastned: EUR34.7m bond issue

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe